Myriad Genetics Inc. has announced the successful closing of a new $200 million credit facility with OrbiMed, a prominent global healthcare investment firm. This five-year senior secured term loan includes $125 million of funded capital, with an option for Myriad to borrow an additional $75 million until June 30, 2027. The facility, which matures on July 31, 2030, bears interest based on the one-month secured overnight financing rate $(SOFR)$ plus 6.50% annually, with a SOFR floor of 2.50%. The credit facility is secured by nearly all of Myriad's assets and replaces the company's previous asset-based lending facility. Evercore acted as the exclusive financial advisor for the transaction. This funding will support Myriad's growth strategy and objectives in the field of molecular diagnostic testing and precision medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.